Condition: Triple-negative Breast Cancer · Sponsor: Shanghai Junshi Bioscience Co., Ltd.
This is an open-label, multi-center, phase II clinical study to preliminarily evaluate the efficacy and safety of JS207 combined with 9MW2821 or albumin paclitaxel as first-line therapy in patients with recurrent or metastatic TNBC.
This description comes directly from the study's public registry record.
Chaoqiang Yang, Master · 18252095266 · chaoqiang_yang@junshipharma.com
Always discuss trial participation with your own doctor first.
| Anhui Provincial Cancer Hospital | Hefei, Anhui, China | Not Yet Recruiting |
| Peking University People's Hospital | Beijing, Beijing Municipality, China | Recruiting |
| The Fifth Medical Center of PLA General Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Guangdong women and children's hospital and health institute | Guangzhou, Guangdong, China | Not Yet Recruiting |
| Affiliated Hospital of Hebei University | Baoding, Hebei, China | Recruiting |
| Harbin Medical University Affiliated Cancer Hospital | Harbin, Heilongjiang, China | Not Yet Recruiting |
| Harbin Medical University Affiliated Cancer Hospital | Harbin, Heilongjiang, China | Not Yet Recruiting |
| Henan Cancer Hospital | Zhangzhou, Henan, China | Recruiting |
| Hubei Cancer Hospital | Wuhan, Hubei, China | Recruiting |
| Jiangsu Cancer Hospital | Nanjing, Jiangsu, China | Recruiting |
| Jiangsu Province Hospital | Nanjing, Jiangsu, China | Not Yet Recruiting |
| Nanchang People'S Hospital | Nanchang, Jiangxi, China | Not Yet Recruiting |
+ 10 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07045311